1
|
Alberca S, Matador E, Iglesias-Sigüenza J, de Gracia Retamosa M, Fernández R, Lassaletta JM, Monge D. Asymmetric cross-aldol reactions of α-keto hydrazones and α,β-unsaturated γ-keto hydrazones with trifluoromethyl ketones. Chem Commun (Camb) 2021; 57:11835-11838. [PMID: 34698741 DOI: 10.1039/d1cc05014a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
α-Keto hydrazones and α,β-unsaturated γ-keto hydrazones are suitable pro-nucleophiles for asymmetric cross-aldol reactions with trifluoromethyl ketones via aza-di(tri)enamine-type intermediates. A quinidine-derived primary amine catalyst affords tertiary trifluoromethylated alcohols in good-to-excellent yields and high enantioselectivities. Subsequent transformations of hydrazono moieties yield appealing fluorinated carboxylic acids, 1,4-dicarbonyls and γ-keto acids.
Collapse
Affiliation(s)
- Saúl Alberca
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain.
| | - Esteban Matador
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain.
| | - Javier Iglesias-Sigüenza
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain.
| | - Ma de Gracia Retamosa
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain. .,Departamento de Química Orgánica e Instituto de Síntesis Orgánica, Universidad de Alicante, Centro de Innovación en Química Avanzada (ORFEO-CINQA), 03080-Alicante, Spain.
| | - Rosario Fernández
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain.
| | - José M Lassaletta
- Instituto de Investigaciones Químicas (CSIC-US) and Centro de Innovación en Química Avanzada (ORFEO-CINQA), Avda. Américo Vespucio, 49, 41092 Sevilla, Spain.
| | - David Monge
- Departamento de Química Orgánica, Universidad de Sevilla and Centro de Innovación en Química Avanzada (ORFEO-CINQA), C/Prof. García González, 1, 41012 Sevilla, Spain.
| |
Collapse
|
2
|
Potamitis C, Siakouli D, Papavasileiou KD, Boulaka A, Ganou V, Roussaki M, Calogeropoulou T, Zoumpoulakis P, Alexis MN, Zervou M, Mitsiou DJ. Discovery of New non-steroidal selective glucocorticoid receptor agonists. J Steroid Biochem Mol Biol 2019; 186:142-153. [PMID: 30321666 DOI: 10.1016/j.jsbmb.2018.10.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 09/19/2018] [Accepted: 10/11/2018] [Indexed: 12/11/2022]
Abstract
Glucocorticoids (GCs) are widely used as potent anti-inflammatory drugs; however, GC therapy is often accompanied by adverse side effects. The anti-inflammatory action of GCs is exerted through the glucocorticoid receptor (GR) in part by antagonizing the pro-inflammatory nuclear factor k B (NF-kB) whereas the majority of side effects are assumed to be mediated by transactivation of GR target genes. We set out to identify novel non-steroidal selective GR agonists (SEGRA) favoring transrepression of NF-kB target genes over transactivation of genes associated with undesirable effects. Our virtual screening protocol was driven by a pharmacophore model based on a pyrrolidinone amide analogue (named as 'compound 12' in Biggadike et al 2009, PNAS USA 106, 18,114) bound to the extended binding pocket of the GR ligand binding domain (GR-LBD). Ambinter library (7.8 million compounds) was queried by our validated pharmacophore hypothesis and the prioritized compounds were biologically evaluated using a series of well-established screening assays. Two structurally similar hits (1 and 13) were identified that bind to GR, induce its translocation to the nucleus, do not mediate transactivation of GR target genes whereas partially repress a number of pro-inflammatory NF-kB target genes, in a GR-dependent manner. Explanatory molecular dynamics (MD) calculations could detail the per-residue interactions accounting for the binding of 1 and 13 to the extended binding pocket of GR. The discovered 1,3-benzothiazole analogs introduce a new class of genuine SEGRA paving the way for hit-to-lead optimization.
Collapse
Affiliation(s)
- Constantinos Potamitis
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Dimitra Siakouli
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Konstantinos D Papavasileiou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece; National Center for Scientific Research "Demokritos", Institute of Nanoscience and Nanotechnology, Molecular Thermodynamics and Modelling of Materials Laboratory, GR-15310 Aghia Paraskevi Attikis, Greece
| | - Athina Boulaka
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Vassiliki Ganou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Marina Roussaki
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Theodora Calogeropoulou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Panagiotis Zoumpoulakis
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Michael N Alexis
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece
| | - Maria Zervou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece.
| | - Dimitra J Mitsiou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 116 35 Athens, Greece.
| |
Collapse
|
3
|
Han J, Ran JX, Chen XP, Wang ZH, Wu FH. Study on the green click-chemistry synthesis of 4-trifluoroacetyl-1,2,3-triazoles. Tetrahedron 2018. [DOI: 10.1016/j.tet.2018.10.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Jiang L, Hu B, Xie X, Zhang Z. Asymmetric carbonyl-ene reaction of trifluoropyruvate catalyzed by Pd(II)-SunPhos complex. Tetrahedron 2017. [DOI: 10.1016/j.tet.2017.10.044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Mszar NW, Mikus MS, Torker S, Haeffner F, Hoveyda AH. Electronically Activated Organoboron Catalysts for Enantioselective Propargyl Addition to Trifluoromethyl Ketones. Angew Chem Int Ed Engl 2017; 56:8736-8741. [PMID: 28560721 DOI: 10.1002/anie.201703844] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Revised: 05/15/2017] [Indexed: 11/11/2022]
Abstract
A broadly applicable, practical, scalable, efficient and highly α- and enantioselective method for addition of a silyl-protected propargyl moiety to trifluoromethyl ketones has been developed. Reactions, promoted by 2.0 mol % of a catalyst that is derived in situ from a readily accessible aminophenol compound at ambient temperature, were complete after only 15 minutes at room temperature. The desired tertiary alcohols were isolated in up to 97 % yield and 98.5:1.5 enantiomeric ratio. Alkyl-, alkenyl-, alkynyl-, aryl- or heteroaryl-substituted trifluoromethyl ketones can be used. Utility is highlighted by application to a transformation that is relevant to enantioselective synthesis of BI 653048, a compound active against rheumatoid arthritis.
Collapse
Affiliation(s)
- Nicholas W Mszar
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, 02467, USA
| | - Malte S Mikus
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, 02467, USA
| | - Sebastian Torker
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, 02467, USA
| | - Fredrik Haeffner
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, 02467, USA
| | - Amir H Hoveyda
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, 02467, USA
| |
Collapse
|
6
|
Mszar NW, Mikus MS, Torker S, Haeffner F, Hoveyda AH. Electronically Activated Organoboron Catalysts for Enantioselective Propargyl Addition to Trifluoromethyl Ketones. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201703844] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Nicholas W. Mszar
- Department of Chemistry; Merkert Chemistry Center; Boston College; Chestnut Hill MA 02467 USA
| | - Malte S. Mikus
- Department of Chemistry; Merkert Chemistry Center; Boston College; Chestnut Hill MA 02467 USA
| | - Sebastian Torker
- Department of Chemistry; Merkert Chemistry Center; Boston College; Chestnut Hill MA 02467 USA
| | - Fredrik Haeffner
- Department of Chemistry; Merkert Chemistry Center; Boston College; Chestnut Hill MA 02467 USA
| | - Amir H. Hoveyda
- Department of Chemistry; Merkert Chemistry Center; Boston College; Chestnut Hill MA 02467 USA
| |
Collapse
|
7
|
Latli B, Reeves JT, Tan Z, Hrapchak M, Song JJ, Busacca CB, Senanayake CH. Synthesis of two potent glucocorticoid receptor agonists labeled with carbon-14 and stable isotopes. J Labelled Comp Radiopharm 2015; 58:445-52. [PMID: 26391408 DOI: 10.1002/jlcr.3349] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 08/21/2015] [Accepted: 08/30/2015] [Indexed: 11/08/2022]
Abstract
Two potent glucocorticoid receptor agonists were prepared labeled with carbon-14 and with stable isotopes to perform drug metabolism, pharmacokinetics, and bioanalytical studies. Carbon-14 labeled (1) was obtained from an enantiopure alkyne (5) via a Sonogashira coupling to a previously reported 5-amino-4-iodo-[2-(14)C]pyrimidine [(14)C]-(6), followed by a base-mediated cyclization (1) in 72% overall radiochemical yield. Carbon-14 labeled (2) was prepared in five steps employing a key benzoic acid intermediate [(14)C]-(13), which was synthesized in one pot from enolization of trifluoromethylketone (12), followed by bromine-magnesium exchange and then electrophile trapping reaction with [(14)C]-carbon dioxide. A chiral auxiliary (S)-1-(4-methoxyphenyl)ethylamine was then coupled to this acid to give [(14)C]-(15). Propargylation and separation of diastereoisomers by crystallizations gave the desired diastereomer [(14)C]-(17) in 34% yield. Sonogashira coupling to iodopyridine (10) followed by cyclization to the azaindole [(14)C]-(18) and finally removal of the chiral auxiliary gave [(14)C]-(2) in 7% overall yield. For stable isotope syntheses, [(13)C6]-(1) was obtained in three steps using [(13)C4]-(6) and trimethylsilylacetylene-[(13)C2] in 26% yield, while [(2)H5]-(2) was obtained by first preparing the iodopyridine [(2)H5]-(10) in five steps. Then, Sonogashira coupling to chiral alkyne (24) and cyclization gave [(2)H5]-(2) in 42% overall yield.
Collapse
Affiliation(s)
- Bachir Latli
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Jonathan T Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Matt Hrapchak
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Jinhua J Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Carl B Busacca
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Chris H Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| |
Collapse
|
8
|
Harcken C, Riether D, Liu P, Razavi H, Patel U, Lee T, Bosanac T, Ward Y, Ralph M, Chen Z, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Zuvela-Jelaska L, Patel M, Thomson DS, Nabozny GH. Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett 2014; 5:1318-23. [PMID: 25516791 DOI: 10.1021/ml500387y] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 11/17/2014] [Indexed: 01/15/2023] Open
Abstract
A series of nonsteroidal "dissociated" glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound ( R )-39.
Collapse
Affiliation(s)
- Christian Harcken
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Doris Riether
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Pingrong Liu
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Hossein Razavi
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Usha Patel
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Thomas Lee
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Todd Bosanac
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Yancey Ward
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Ralph
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Zhidong Chen
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donald Souza
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Richard M. Nelson
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Alison Kukulka
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Tazmeen N. Fadra-Khan
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Ljiljana Zuvela-Jelaska
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mita Patel
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - David S. Thomson
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Gerald H. Nabozny
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| |
Collapse
|
9
|
Kucher OV, Kolodiazhnaya AO, Smolii OB, Prisuazhnyk DV, Tolmacheva KA, Zaporozhets OA, Moroz YS, Mykhailiuk PK, Tolmachev AA. Enzyme-Catalyzed Kinetic Resolution of 2,2,2-Trifluoro-1-(heteroaryl)ethanols: Experimental and Docking Studies. European J Org Chem 2014. [DOI: 10.1002/ejoc.201403013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
10
|
Razavi H, Riether D, Harcken C, Bentzien J, Dinallo RM, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Pack EJ, Zuvela-Jelaska L, Pelletier J, Panzenbeck M, Torcellini CA, Proudfoot JR, Nabozny GH, Thomson DS. Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. Bioorg Med Chem Lett 2014; 24:1934-40. [DOI: 10.1016/j.bmcl.2014.03.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 02/27/2014] [Accepted: 03/03/2014] [Indexed: 10/25/2022]
|
11
|
Harcken C, Riether D, Kuzmich D, Liu P, Betageri R, Ralph M, Emmanuel M, Reeves JT, Berry A, Souza D, Nelson RM, Kukulka A, Fadra TN, Zuvela-Jelaska L, Dinallo R, Bentzien J, Nabozny GH, Thomson DS. Identification of Highly Efficacious Glucocorticoid Receptor Agonists with a Potential for Reduced Clinical Bone Side Effects. J Med Chem 2014; 57:1583-98. [DOI: 10.1021/jm4019178] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Christian Harcken
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Doris Riether
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Daniel Kuzmich
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Pingrong Liu
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Raj Betageri
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Ralph
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Michel Emmanuel
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Jonathan T. Reeves
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Angela Berry
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donald Souza
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Richard M. Nelson
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Alison Kukulka
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Tazmeen N. Fadra
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Ljiljana Zuvela-Jelaska
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Roger Dinallo
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Jörg Bentzien
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Gerald H. Nabozny
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - David S. Thomson
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| |
Collapse
|
12
|
Chikkade PK, Shimizu Y, Kanai M. Catalytic enantioselective synthesis of 2-(2-hydroxyethyl)indole scaffolds via consecutive intramolecular amido-cupration of allenes and asymmetric addition of carbonyl compounds. Chem Sci 2014. [DOI: 10.1039/c3sc52803k] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
13
|
Reeves JT, Fandrick DR, Tan Z, Song JJ, Rodriguez S, Qu B, Kim S, Niemeier O, Li Z, Byrne D, Campbell S, Chitroda A, DeCroos P, Fachinger T, Fuchs V, Gonnella NC, Grinberg N, Haddad N, Jäger B, Lee H, Lorenz JC, Ma S, Narayanan BA, Nummy LJ, Premasiri A, Roschangar F, Sarvestani M, Shen S, Spinelli E, Sun X, Varsolona RJ, Yee N, Brenner M, Senanayake CH. Development of a Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist BI 653048 BS H3PO4. J Org Chem 2013; 78:3616-35. [DOI: 10.1021/jo400079z] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jonathan T. Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Daniel R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Jinhua J. Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Sonia Rodriguez
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Bo Qu
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Soojin Kim
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Oliver Niemeier
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Zhibin Li
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Denis Byrne
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Scot Campbell
- Analytical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O.
Box 368, Ridgefield, Connecticut, 06877-0368, United States
| | - Ashish Chitroda
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Phil DeCroos
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Thomas Fachinger
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Victor Fuchs
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nina C. Gonnella
- Analytical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O.
Box 368, Ridgefield, Connecticut, 06877-0368, United States
| | - Nelu Grinberg
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nizar Haddad
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Burkhard Jäger
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Heewon Lee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Jon C. Lorenz
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Shengli Ma
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Bikshandarkoil A. Narayanan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Larry J. Nummy
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Ajith Premasiri
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Frank Roschangar
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Max Sarvestani
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Sherry Shen
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Earl Spinelli
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Xiufeng Sun
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Richard J. Varsolona
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nathan Yee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Michael Brenner
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Chris H. Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| |
Collapse
|
14
|
Fandrick DR, Reeves JT, Bakonyi JM, Nyalapatla PR, Tan Z, Niemeier O, Akalay D, Fandrick KR, Wohlleben W, Ollenberger S, Song JJ, Sun X, Qu B, Haddad N, Sanyal S, Shen S, Ma S, Byrne D, Chitroda A, Fuchs V, Narayanan BA, Grinberg N, Lee H, Yee N, Brenner M, Senanayake CH. Zinc Catalyzed and Mediated Asymmetric Propargylation of Trifluoromethyl Ketones with a Propargyl Boronate. J Org Chem 2013; 78:3592-615. [DOI: 10.1021/jo400080y] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Daniel R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Jonathan T. Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Johanna M. Bakonyi
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Prasanth R. Nyalapatla
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Oliver Niemeier
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Deniz Akalay
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Keith R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Wolfgang Wohlleben
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Swetlana Ollenberger
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Jinhua J. Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Xiufeng Sun
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Bo Qu
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nizar Haddad
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Sanjit Sanyal
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Sherry Shen
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Shengli Ma
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Denis Byrne
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Ashish Chitroda
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Victor Fuchs
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Bikshandarkoil A. Narayanan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nelu Grinberg
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Heewon Lee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nathan Yee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Michael Brenner
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Chris H. Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| |
Collapse
|
15
|
RAZAVI HOSSEIN, HARCKEN CHRISTIAN. Non-steroidal Dissociated Glucocorticoid Receptor Agonists. ANTI-INFLAMMATORY DRUG DISCOVERY 2012. [DOI: 10.1039/9781849735346-00481] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Synthetic glucocorticoids, such as dexamethasone and prednisolone, are amongst the most commonly used drugs due to their potent and efficacious anti-inflammatory and immunosuppressive properties. However, their long-term and/or high-dose administration is limited by a number of deleterious side-effects, including glucocorticoid-induced diabetes and osteoporosis. Glucocorticoids exert their effects through binding to the glucocorticoid receptor. Since the discovery of multiple differentiated down-stream functions of the glucocorticoid-bound receptor, such as gene transrepression and transactivation, researchers in academia and industry have been on a quest to discover novel glucocorticoids that achieve functional selectivity, hence dissociating the desired anti-inflammatory from the undesired side-effects. This review describes the current state of discovery and development of non-steroidal glucocorticoid receptor agonists. Several small-molecule drug candidates have advanced into clinical trials, and have shown promising early biomarker data, as well as beneficial effects in topical applications. However, a clinically efficacious and systemically available glucocorticoid with significantly reduced side-effects as compared to current steroidal drugs, the “Holy Grail” in immunology, is still elusive.
Collapse
Affiliation(s)
- HOSSEIN RAZAVI
- Department of Medicinal Chemistry Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 USA
| | - CHRISTIAN HARCKEN
- Department of Research Networking & Strategic Planning Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 USA
| |
Collapse
|